12.81BMarket Cap35.77P/E (TTM)
69.750High68.000Low1.56MVolume68.540Open68.550Pre Close107.70MTurnover0.85%Turnover Ratio40.64P/E (Static)186.52MShares72.48752wk High8.90P/B12.62BFloat Cap59.20152wk Low1.85Dividend TTM183.70MShs Float82.996Historical High2.69%Div YieldTTM2.55%Amplitude2.174Historical Low69.047Avg Price1Lot Size
Equity Lifestyle Properties Inc Stock Forum
Gap Ups
1. $Zions Bancorp(ZION.US)$ - up 4.0%
2. $Equity Lifestyle Properties Inc(ELS.US)$ - up 3.6%
3. $Novo-Nordisk A/S(NVO.US)$ - up 1.7%
4. $Freeport-McMoRan(FCX.US)$ - up 1.4%
5. $Orange SA(ORAN.US)$ - up 0.9%
6. $Sanofi(SNY.US)$ - up 0.9%
7. $Catalent(CTLT.US)$ - up 0.9%
8. $Tenaris(TS.US)$ - up 0.9...
• $Allogene Therapeutics(ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX(CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp(CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC(FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern(NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...
• $Arcturus Therapeutics(ARCT.US)$ : Baird Upgrades to Neutral from Underperform - PT $18 (from $21)
• $Arrowhead Pharmaceuticals(ARWR.US)$ : Baird Upgrades to Outperform from Neutral - PT $60 (from $71)
• $Cronos Group(CRON.US)$ : CIBC Upgrades to Outperformer from Neutral
• $HF Sinclair(DINO.US)$ : Cowen Upgrades to Outperform from Market Perform - PT $52 (from $38)
• $8x8(EGHT.US)$ : B. Riley Upgrades to Buy from Neutral - PT $13.50
• $Novanta(NOVT.US)$ : William...
• $Checkmate Pharmaceuticals(CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $Axsome Therapeutics(AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $Super Micro Computer(SMCI.US)$ +14.3% (earnings report)
• $Plug Power(PLUG.US)$ +9.24% (t...
No comment yet